Ecolab Life Sciences, a US-based infection prevention specialist, has announced the launch of Klercide Rapid Sporicide.
The new product is a new sporicidal disinfectant designed specifically for cleanroom applications in pharma production.
“Cleanroom operators and pharmaceutical manufacturers have long sought a sporicide solution that balances efficacy and usability,” said Meg Carr, VP & General Manager of Ecolab Life Sciences.
In pharmaceutical manufacturing, contamination can halt production, compromise safety and drain margins. That’s why controlling spores, fungi and other hard-to-kill microorganisms in cleanrooms isn’t just incidental, it’s critical.
Existing sporicides often bring trade-offs: strong odours, corrosiveness, long turnaround times, and risk to equipment longevity.
Existing alternatives in the market are often chlorine or peroxide-based
Ecolab claims that the Klercide Rapid Sporicide delivers “efficacy while minimising residue, reducing re-application time and enhancing overall user experience.”
For pharmaceutical manufacturers under pressure to increase throughput, reduce change-over time and maintain regulatory compliance, those operational gains make a difference.
Unlike many traditional sporicides, the Klercide Rapid Sporicide is based on a combination of peracetic acid and hydrogen peroxide rather than a chlorine-derived chemistry.
Existing alternatives in the market are often chlorine-based, such as sodium hypochlorite or chlorine dioxide, or peroxide-based.
The new formulation from Ecolab reflects a strategic shift toward balancing efficacy, equipment compatibility and operator usability.
The company also claims that the product is milder on equipment and surfaces, making it more compatible with delicate cleanroom hardware.
Ecolab’s recent activity
Ecolab Life Sciences is bolstering its footprint across innovation, processing and sustainability.
In the pharmaceutical and biotech space, it launched the Purolite (trademarked) AP+50 resin, a high-capacity affinity chromatography solution built on proprietary jetted-bead manufacturing, aimed at reducing purification costs and accelerating processing of monoclonal antibodies.
Alongside product innovation, Ecolab has also opened a bioprocessing applications laboratory in Pennsylvania, outfitted with high-throughput tools and full-scale chromatography columns to support CDMOs and biopharma firms through the entire development and manufacturing cycle.
On the sustainability front, Ecolab has partnered with Low Carbon to power all its European operations with renewable electricity. Operations are now powered by a Finnish wind-farm project that yields about 100 GWh annually and reduces over 20,000 tonnes CO₂ each year.
Through these advances in new products, facilities and energy sustainability, Ecolab is signalling a strategy that combines operational excellence with environmental responsibility.
